Triple-negative breast cancer (TNBC), defined by the lack of expression of oestrogen and progesterone receptors (ER and PR, respectively) and associated with the absence of HER2 overexpression/amplification, represents approximately 15% of cases of early stage invasive breast cancer [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.